290 related articles for article (PubMed ID: 31138870)
21. The influencing factors and functions of DNA G-quadruplexes.
Yuan WF; Wan LY; Peng H; Zhong YM; Cai WL; Zhang YQ; Ai WB; Wu JF
Cell Biochem Funct; 2020 Jul; 38(5):524-532. PubMed ID: 32056246
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic applications of AS1411 aptamer, an update review.
Yazdian-Robati R; Bayat P; Oroojalian F; Zargari M; Ramezani M; Taghdisi SM; Abnous K
Int J Biol Macromol; 2020 Jul; 155():1420-1431. PubMed ID: 31734366
[TBL] [Abstract][Full Text] [Related]
23. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
[TBL] [Abstract][Full Text] [Related]
24. Exploring the conformational behaviour and aggregation properties of lipid-conjugated AS1411 aptamers.
Riccardi C; Musumeci D; Russo Krauss I; Piccolo M; Irace C; Paduano L; Montesarchio D
Int J Biol Macromol; 2018 Oct; 118(Pt B):1384-1399. PubMed ID: 30170359
[TBL] [Abstract][Full Text] [Related]
25. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.
Girvan AC; Teng Y; Casson LK; Thomas SD; Jüliger S; Ball MW; Klein JB; Pierce WM; Barve SS; Bates PJ
Mol Cancer Ther; 2006 Jul; 5(7):1790-9. PubMed ID: 16891465
[TBL] [Abstract][Full Text] [Related]
26. Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.
Noaparast Z; Hosseinimehr SJ; Piramoon M; Abedi SM
J Drug Target; 2015; 23(6):497-505. PubMed ID: 25673264
[TBL] [Abstract][Full Text] [Related]
27. AS1411 Nucleolin-Specific Binding Aptamers Reduce Pathological Angiogenesis through Inhibition of Nucleolin Phosphorylation.
Iturriaga-Goyon E; Vivanco-Rojas O; Magaña-Guerrero FS; Buentello-Volante B; Castro-Salas I; Aguayo-Flores JE; Gracia-Mora I; Rivera-Huerta M; Sánchez-Bartés F; Garfias Y
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884955
[TBL] [Abstract][Full Text] [Related]
28. Delivery, Effect on Cell Viability, and Plasticity of Modified Aptamer Constructs.
Gissberg O; Zaghloul EM; Lundin KE; Nguyen CH; Landras-Guetta C; Wengel J; Zain R; Smith CI
Nucleic Acid Ther; 2016 Jun; 26(3):183-9. PubMed ID: 26859550
[TBL] [Abstract][Full Text] [Related]
29. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
30. Truncated G-Quadruplex Isomers Cross-Talk with the Transcription Factors To Maintain Homeostatic Equilibria in c-MYC Transcription.
Sengupta P; Bhattacharya A; Sa G; Das T; Chatterjee S
Biochemistry; 2019 Apr; 58(15):1975-1991. PubMed ID: 30920805
[TBL] [Abstract][Full Text] [Related]
31. Targeted delivery of melittin to cancer cells by AS1411 anti-nucleolin aptamer.
Rajabnejad SH; Mokhtarzadeh A; Abnous K; Taghdisi SM; Ramezani M; Razavi BM
Drug Dev Ind Pharm; 2018 Jun; 44(6):982-987. PubMed ID: 29325460
[TBL] [Abstract][Full Text] [Related]
32. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin.
Teng Y; Girvan AC; Casson LK; Pierce WM; Qian M; Thomas SD; Bates PJ
Cancer Res; 2007 Nov; 67(21):10491-500. PubMed ID: 17974993
[TBL] [Abstract][Full Text] [Related]
33. Nucleolin-targeted Extracellular Vesicles as a Versatile Platform for Biologics Delivery to Breast Cancer.
Wang Y; Chen X; Tian B; Liu J; Yang L; Zeng L; Chen T; Hong A; Wang X
Theranostics; 2017; 7(5):1360-1372. PubMed ID: 28435471
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.
Holmboe S; Hansen PL; Thisgaard H; Block I; Müller C; Langkjær N; Høilund-Carlsen PF; Olsen BB; Mollenhauer J
PLoS One; 2017; 12(5):e0178286. PubMed ID: 28542563
[TBL] [Abstract][Full Text] [Related]
35. Characterizing Oligonucleotide Uptake in Cultured Cells: A Case Study Using AS1411 Aptamer.
Reyes-Reyes EM; Bates PJ
Methods Mol Biol; 2019; 2036():173-186. PubMed ID: 31410797
[TBL] [Abstract][Full Text] [Related]
36. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery.
Wu J; Song C; Jiang C; Shen X; Qiao Q; Hu Y
Mol Pharm; 2013 Oct; 10(10):3555-63. PubMed ID: 23679916
[TBL] [Abstract][Full Text] [Related]
37. Bioactivity of 2'-deoxyinosine-incorporated aptamer AS1411.
Fan X; Sun L; Wu Y; Zhang L; Yang Z
Sci Rep; 2016 May; 6():25799. PubMed ID: 27194215
[TBL] [Abstract][Full Text] [Related]
38. Aptamer-Aptamer Chimera for Targeted Delivery and ATP-Responsive Release of Doxorubicin into Cancer Cells.
Esawi E; Alshaer W; Mahmoud IS; Alqudah DA; Azab B; Awidi A
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884745
[TBL] [Abstract][Full Text] [Related]
39. Polyethylenimine-functionalized carbon nanotubes tagged with AS1411 aptamer for combination gene and drug delivery into human gastric cancer cells.
Taghavi S; Nia AH; Abnous K; Ramezani M
Int J Pharm; 2017 Jan; 516(1-2):301-312. PubMed ID: 27840158
[TBL] [Abstract][Full Text] [Related]
40. Nanoaggregate-forming lipid-conjugated AS1411 aptamer as a promising tumor-targeted delivery system of anticancer agents in vitro.
Carvalho J; Lopes-Nunes J; Vialet B; Rosado T; Gallardo E; Vale J; Eloy C; Ferreira S; Palmeira-de-Oliveira R; Campello MPC; Paulo A; Barthélémy P; Mergny JL; Salgado GF; Queiroz JA; Ellington AD; Cruz C
Nanomedicine; 2021 Aug; 36():102429. PubMed ID: 34174419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
